abacavir/lamivudine

{{Short description|Combination drug for HIV}}

{{Infobox drug

| Verifiedfields = changed

| verifiedrevid = 448004176

| image = Abacavir and lamivudine.svg

| image_class = skin-invert-image

| width = 200

| type = combo

| component1 = Abacavir

| class1 = Nucleotide analogue reverse transcriptase inhibitor

| component2 = Lamivudine

| class2 = Nucleotide analogue reverse transcriptase inhibitor

| tradename = Kivexa, Epzicom, others

| Drugs.com = {{drugs.com|ppa|abacavir-and-lamivudine}}

| MedlinePlus = a696011

| pregnancy_AU = B3

| pregnancy_category =

| routes_of_administration = By mouth

| ATC_prefix = J05

| ATC_suffix = AR02

| legal_AU = S4

| legal_AU_comment ={{cite web | title=CAVADEXA, ABADINE, ABALAMID HETERO, BACAMID, LAMAVIR 600/300 (Hetero Australia Pty Ltd) | website=Therapeutic Goods Administration (TGA) | date=13 January 2023 | url=https://www.tga.gov.au/resources/prescription-medicines-registrations/cavadexa-abadine-abalamid-hetero-bacamid-lamavir-600300-hetero-australia-pty-ltd | access-date=15 April 2023}}

| legal_BR =

| legal_BR_comment =

| legal_CA = Rx-only

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK = POM

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment =

| legal_EU = Rx-only

| legal_EU_comment = {{cite web | title=Kivexa EPAR | website=European Medicines Agency | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa | access-date=16 November 2020}}

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number =  136470-78-5

| CAS_number2_Ref = {{cascite|correct|CAS}}

| CAS_number2 = 134678-17-4

| PubChem = 5273759

| DrugBank_Ref =

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = WR2TIP26VS

| UNII2_Ref = {{fdacite|correct|FDA}}

| UNII2 = 2T8Q726O95

| KEGG = D08775

| NIAID_ChemDB = 225604

}}

Abacavir/lamivudine, sold under the brand name Kivexa among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains abacavir and lamivudine. It is generally recommended for use with other antiretrovirals. It is commonly used as part of the preferred treatment in children.{{cite book | vauthors = ((World Health Organization)) | year = 2015 | title = The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children) | publisher = World Health Organization | location = Geneva | author-link = World Health Organization | hdl = 10665/189763 | id = WHO technical report series;994 | hdl-access=free | isbn = 9789241209946 | issn = 0512-3054 |pages=45–46 }} It is taken by mouth as a tablet.{{cite web|title=Abacavir and Lamivudine Tablets|url=https://www.drugs.com/pro/abacavir-and-lamivudine-tablets.html|publisher=Teva Pharmaceuticals USA|access-date=28 November 2016|url-status=live|archive-url=https://web.archive.org/web/20170206022505/https://www.drugs.com/pro/abacavir-and-lamivudine-tablets.html|archive-date=6 February 2017}}

Common side effects include trouble sleeping, headache, depression, feeling tired, nausea, rash, and fever. Serious side effects may include high blood lactate levels, allergic reactions, and enlargement of the liver. It is not recommended in people with a specific gene known as HLA-B*5701. Safety in pregnancy has not been well studied but it appears to be okay.{{cite web|title=Abacavir / lamivudine (Epzicom) Use During Pregnancy|url=https://www.drugs.com/pregnancy/abacavir-lamivudine.html|website=www.drugs.com|access-date=4 December 2016|url-status=live|archive-url=https://web.archive.org/web/20161220201915/https://www.drugs.com/pregnancy/abacavir-lamivudine.html|archive-date=20 December 2016}} Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).

Abacavir/lamivudine was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines.{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}